NEW YORK–(BUSINESS WIRE)–Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science. Both executives will be joining the company’s leadership team to drive innovation in data science at Koneksa. They will focus on applying data science to unlock valuable insights and knowledge from clinical trial data. Dr. Robert Ellis, current Head of Data Science and Co-founder, Koneksa, will transition to Head of Biomarker Exploration.
“Koneksa has more than a petabyte of data collected using the highest clinical standards across more than 40 studies and from over 4500 subjects,” said Chris Benko, CEO of Koneksa. “Dave and Larsson will be helming a data team fueled by far more raw data than any similar organization and developing new tools and solutions for our clients with that power. Their combined perspectives and leadership will enable us to scale our efforts and deliver exceptional value to our partners and clients.”
Dave Hurry brings more than 30 years of experience in computer science research to Koneksa. He was previously Head of Data Services and Content Delivery at Takeda, where he brought together their broad range of R&D data and advanced tools to accelerate data science, artificial intelligence and machine learning. Prior to Takeda, Dave was Executive Director, Computer Science at Merck, where he delivered new solutions combining and connecting data for research, manufacturing, and commercial needs. Before joining the pharmaceutical industry, Dave spent more than 25 years at the National Security Agency, where he held multiple senior leadership positions including Chief of Computer Science Research. Dave’s leadership and expertise have been recognized with numerous honors including the United States Distinguished Presidential Rank Award, the United States Meritorious Presidential Rank Award, and the NSA Exceptional Civilian Service Award. He is a patent holder for his groundbreaking computer science inventions in life sciences. Dave holds a master’s of engineering in electrical engineering and a bachelor of science in electrical engineering from Cornell University.
Dr. Larsson Omberg’s appointment brings a unique blend of data science, computational biology, research management, and clinical perspective to Koneksa. Larsson was previously Head of the Systems Biology and Digital Health Research groups at Sage Bionetworks. He has a masters in engineering from The KTH Royal Institute of Technology in Sweden, and a PhD in physics from UT Austin, and trained in computational biology and biostatistics through a postdoctoral fellowship at Cornell University. His leadership has been instrumental in both collaborative multi-omics research and in digital health, where he has worked with several pharmaceutical companies across a range of conditions from chronic anemia through heart disease and neurodegenerative conditions. Larsson has demonstrated his ability to bridge the gap between academia and industry, propelling the field towards impactful solutions.
“Koneksa is positioned to revolutionize the way data science is leveraged in drug development,” said Hurry. “By embracing new devices and new biomarkers, Koneksa is about data science and data platforms that keep up with the pace of change. Koneksa’s ability to develop solutions using their own unparalleled stores of clinical data and a platform that adapts as fast as the data presents an exciting opportunity to transform the healthcare landscape. I look forward to working with my new colleagues to improve patient outcomes and improve care.”
“Both Dave and I have shared a mission for some time with Koneksa: accelerating our ability to unlock the potential of clinical health data,” said Omberg. “We’re not aiming lower than a real revolution in clinical trials. We share an unwavering commitment to improving lives through innovative digital solutions.”
“I have had the opportunity to create the data science team at Koneksa and support its growth and delivery as an integral part of our platform and services offerings,” said Ellis. “The team is in good hands as I shift my focus earlier in the pipeline, to identify and nurture opportunities to fuel Koneksa’s growth.”
Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.